GSK2606414 is a drug which is the first in a new class of drugs which are designed to treat schizophrenia.  GSK2606414 is a drug which is the first in a new class of drugs which are designed to treat schizophrenia. The drug is thought to work by targeting the neurotransmitter dopamine, which is believed to be responsible for the symptoms of schizophrenia. GSK2606414 is currently being developed by GSK, and has been deemed as a potential breakthrough treatment for the condition.
